Morphic Therapeutic
Biotechnology company developing a new generation of oral integrin therapies.
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 406 % | 165 % | (56 %) | 258 % | (99 %) | (52 %) | 32 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (272 %) | (105 %) | (484 %) | (90 %) | (34087 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (255 %) | (100 %) | (483 %) | (83 %) | (29193 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 316 % | 164 % | 444 % | 144 % | 26945 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Morphic Therapeutic is at the forefront of developing a new generation of oral integrin drugs, leveraging decades of expertise and a unique integrin discovery platform. The company aims to revolutionize the treatment landscape for patients suffering from serious chronic diseases such as autoimmune disorders, cardiovascular conditions, metabolic diseases, fibrosis, and cancer.
Morphic operates in the biopharmaceutical industry, targeting a specialized market of patients with chronic and severe health conditions. The company's business model revolves around the research, development, and commercialization of oral integrin drugs. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved drugs.
Morphic's integrin platform is supported by significant partnerships with major healthcare investors and organizations, which provide both financial backing and strategic guidance. The company is led by a team of experienced scientists and industry leaders, including founder Timothy Springer, PhD, and Chief Scientific Officer Shelia Violette, PhD.
The company’s innovative approach focuses on making integrin-targeting therapies more accessible and effective by developing oral formulations, which could offer a more convenient alternative to current treatments that often require injections or infusions.
Keywords: oral integrin drugs, chronic diseases, autoimmune, cardiovascular, fibrosis, cancer, biopharmaceutical, integrin platform, partnerships, commercialization.